US · Healthcare · Biotechnology
EPS came in at 0.47 against a street estimate of -0.44 — a beat of 206.8%.
Analysts rate enGene Holdings Inc. Common Stock a buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $3.29.
| Fund | Stake |
|---|---|
| BML Capital Management LLC | 9.95% |
| Siren, L.L.C. | 7.84% |
| Perceptive Advisors LLC | 7.20% |
| BRAIDWELL LP | 3.67% |
| Nextech Invest, Ltd. | 3.47% |
| Franklin Templeton Inc | 1.96% |
| Polar Capital Holdings PLC | 1.83% |
| Balyasny Asset Management LLC | 1.71% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for enGene Holdings Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.